Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Hypertension Medication

  • Author: Meena S Madhur, MD, PhD; Chief Editor: David J Maron, MD, FACC, FAHA  more...
 
Updated: Sep 30, 2014
 

Medication Summary

Many therapeutic agents can be used for the pharmacologic management of hypertension. The general recommendation established by JNC-7 is to initiate a thiazide-type diuretic initially for stage 1 hypertensives without compelling indications for other therapies.[3] Drugs such as angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), angiotensin receptor blockers (ARBs), beta-blockers, and diuretics are all considered acceptable alternative therapies in patients with hypertension.[3] The available antihypertensive agents are generally equally effective in lowering blood pressure however; there may be interpatient variability that can affect the way a patient will respond to one treatment over another.

Next

Diuretics, Thiazide

Class Summary

Thiazide diuretics are used as monotherapy, or they can be administered adjunctively with other antihypertensive agents. Thiazide diuretics inhibit reabsorption of sodium and chloride mostly in the distal tubules. Long-term use of these drugs may result in hyponatremia.[95]

They also increase potassium and bicarbonate excretion and decrease calcium excretion and uric acid retention. Thiazides do not affect normal blood pressure.

Keep in mind that all available loop and thiazide diuretic agents, except ethacrynic acid, possess a sulfonamide group, which has important clinical relevance to those individuals with allergies to sulfonamide agents.

Hydrochlorothiazide (Microzide)

 

Hydrochlorothiazide is approved for the management of hypertension, alone or in combination with other antihypertensive agents. Unlike potassium-sparing combination diuretic products, hydrochlorothiazide may be used in patients who cannot risk the development of hyperkalemia, including patients taking ACE inhibitors.

Hydrochlorothiazide is available as oral tablets or capsules in doses ranging from 12.5-50 mg. The usual dose is 12.5 mg given alone or in combination with other antihypertensives, with a maximum dose of 50 mg daily. Doses greater than 50 mg are associated with hypokalemia.

Chlorthalidone (Thalitone)

 

Chlorthalidone is indicated for the management of hypertension either alone or in combination with other antihypertensives. The initial dosage is 25 mg as a single daily dose. Dosage can be titrated to 50 mg if the clinical response is not adequate. If additional control is required, increase the dosage to 100 mg once daily, or a second antihypertensive drug may be added. Doses greater than 100 mg daily usually do not increase effectiveness. Increases in serum uric acid and hypokalemia are dose-related over the 25-100 mg/day range.

Metolazone (Zaroxolyn)

 

Metolazone is approved for the treatment of hypertension either alone (uncommon) or in combination with other antihypertensives. The initial dosage for hypertension is 2.5 to 5 mg given once daily. Metolazone does not decrease glomerular filtration rate or the renal plasma flow and may be a more effective option for patients with impaired renal function.

Indapamide

 

Indapamide is chemically not a thiazide, although its structure and function are very similar. The drug enhances the excretion of sodium, chloride, and water by inhibiting the transport of sodium ions across the renal tubule. The hypovolemic action of indapamide is believed to be responsible for the drug's beneficial cardiovascular effects. The half-life of indapamide is approximately 14 hours, so the drug can be taken just once daily. Adverse effects tend to be somewhat milder than with thiazides.

Previous
Next

Diuretic, Potassium-Sparing

Class Summary

The potassium-sparing diuretics interfere with sodium reabsorption at the distal tubules (primarily in the collecting duct region of the nephron), decreasing potassium secretion. Potassium-sparing diuretics have a weak diuretic and antihypertensive effect when used alone.

Triamterene

 

Triamterene is used alone or with other medications (often a kaliuretic diuretic such as hydrochlorothiazide) to treat edema and high blood pressure. Because triamterene increases potassium levels, caution is required when combining triamterene with ACE inhibitors, angiotensin receptor blockers, aliskiren, and other drugs that increase potassium levels. Potassium level should be monitored at start of treatment, dose change, and during illness that affects renal function. The recommended dose is 100 mg twice daily (maximum dose is 300 mg/d).

Amiloride (Midamor)

 

Amiloride is a potassium-conserving (antikaliuretic) drug that, compared with thiazide diuretics, possesses weak natriuretic, diuretic, and antihypertensive activity. It is approved as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents for hypertension or congestive heart failure. It is unrelated chemically to other known antikaliuretic or diuretic agents. Amiloride has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride can be given at a dose of 5-10 mg daily in 1-2 divided doses for hypertension. Amiloride has a black box warning for hyperkalemia, which, if not corrected, is potentially fatal. This incidence is greater in patients with renal impairment or diabetes mellitus and in the elderly.

Previous
Next

Diuretics, Loop

Class Summary

Loop diuretics act on the ascending limb of the loop of Henle, inhibiting the reabsorption of sodium and chloride. The loop diuretics are highly protein-bound and therefore enter the urine primarily by tubular secretion in the proximal tubule, rather than by glomerular filtration.

Loop diuretics are commonly used to control volume retention. Generally, thiazide diuretics are recommended for most patients with a diagnosis of hypertension; however, loop diuretics are more commonly prescribed for patients with decreased glomerular filtration rate or heart failure. Loop diuretics do not reduce blood pressure as effectively as thiazide diuretics when they are used as monotherapy, especially if they are dosed once daily.

Keep in mind that all available loop and thiazide diuretic agents, except ethacrynic acid, possess a sulfonamide group, which has important clinical relevance to those individuals with allergies to sulfonamide agents.

Furosemide (Lasix)

 

Furosemide is approved for the treatment of hypertension alone (uncommon) or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. The initial dosing recommendations for hypertension are usually 80 mg (divided into 40 mg twice a day). If clinical response is not sufficient, additional antihypertensives may be added. Patients should be monitored carefully because furosemide is a potent diuretic. If given in excessive amounts, it can cause profound diuresis with water and electrolyte depletion. Furosemide is available as an oral tablet and injection solution.

Torsemide (Demadex)

 

Torsemide can be used as monotherapy or in combination with other antihypertensive agents. The initial dose is 5 mg once daily. The dose can be titrated to 10 mg once daily. If adequate response is not seen, an additional antihypertensive agent may be needed. Torsemide is available as an oral tablet and injection solution.

Bumetanide

 

Bumetanide is FDA approved for the treatment of edema. It is also used off-label for the treatment of hypertension. The usual dosage range for bumetanide for hypertension is 0.5-2 mg/day given once or twice a day.[3]

Previous
Next

ACE Inhibitors

Class Summary

Angiotensin converting enzyme (ACE) inhibitors are the treatment of choice in patients with hypertension, chronic kidney disease, and proteinuria. ACE inhibitors reduce morbidity and mortality rates in patients with heart failure, patients with recent myocardial infarctions, and patients with proteinuric renal disease. ACE inhibitors appear to act primarily through suppression of the renin-angiotensin-aldosterone system. ACE inhibitors prevent the conversion of angiotensin I to angiotensin II and block the major pathway of bradykinin degradation by inhibiting ACE. Accumulation of bradykinin has been proposed as an etiologic mechanism for the side effects of cough and angioedema. ACE inhibitors can cause injury or even death to a developing fetus. In pregnant patients, ACE inhibitors should be discontinued as soon as possible.

It is important to note that the blood-pressure-lowering effects of ACE inhibitors and thiazides are approximately additive, and there is also the potential for hyperkalemia when ACE inhibitors are coadministered with potassium supplements or potassium-sparing diuretics. In addition, a study by Harel et al found an increased risk for hyperkalemia when aliskiren, a direct renin inhibitor, and ACE inhibitors or angiotensin receptor blockers were used together.[96] Careful monitoring of serum potassium levels is warranted when these agents are used in combination.[96] Furthermore, in patients with hypertension plus type 2 diabetes and renal impairment who are at high risk of cardiovascular and renal events, there is an increased risk of nonfatal stroke, renal complications, hypokalemia, and hypotension when aliskiren is added to ACE inhibitor or ARB therapy.

Fosinopril

 

Fosinopril may be used alone or in combination with other antihypertensive agents. Initial dose is 5 mg daily up to a maximum of 40 mg daily. May be divided into twice daily dosing. Unlike most ACE inhibitors that are primarily excreted by the kidneys, fosinopril is eliminated by both renal and hepatic pathways, making it a safer choice in patients with renal failure and heart failure patients with impaired kidney function.

Captopril

 

Captopril is indicated for the treatment of hypertension. It can be used alone or in combination with other antihypertensive drugs, such as diuretics or beta-adrenergic-blocking agents. The initial dose is 25 mg given 2 to 3 times daily. If reduction of blood pressure is not achieved after 1 or 2 weeks, the dose can be titrated to 50 mg 2 or 3 times daily. If further blood reduction is required after addition of a diuretic, the dose of captopril may be increased to 100 mg 2 or 3 times daily and then, if necessary, to 150 mg 2 or 3 times daily (while continuing the diuretic).

Ramipril (Altace)

 

Ramipril is indicated for the treatment of hypertension alone or in combination with thiazide diuretics. The initial dosing recommendation for ramipril is 2.5 mg daily for patients who are not receiving a diuretic. Doses can range from 2.5-20 mg/day given once or twice a day.

Enalapril (Vasotec)

 

Enalapril is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The initial dose of enalapril is 5 mg daily. Dosage can range from 10-40 mg/day administered as a single dose or in 2 divided doses.

Lisinopril (Prinivil, Zestril)

 

Lisinopril may be used as monotherapy or concomitantly with other classes of antihypertensive agents. The initial dose of lisinopril is 10 mg daily. The dosage can range from 20-40 mg/day as a single daily dose. Doses up to 80 mg/day have been used; however, they do not show a greater effect.

Quinapril (Accupril)

 

Quinapril may be used alone or in combination with thiazide diuretics. The initial dose is 10 to 20 mg daily for patients not on diuretics. If blood pressure is not controlled with quinapril monotherapy, adding a diuretic should be considered.

Previous
Next

ARBs

Class Summary

Generally, ACE inhibitors should remain the initial treatment of choice for hypertension. Angiotensin II receptor antagonists or angiotensin receptor blockers (ARBs) are used for patients who are unable to tolerate ACE inhibitors. ARBs competitively block binding of angiotensin-II to angiotensin type I (AT1) receptors, thereby reducing effects of angiotensin II–induced vasoconstriction, sodium retention, and aldosterone release; the breakdown of bradykinin should not be inhibited. If monotherapy with an ARB is not sufficient, adding a diuretic should be considered.

ARBs can cause injury or even death to a developing fetus. If a patient becomes pregnant, ARBs should be discontinued as soon as possible.

Note that a study by Harel et al found an increased risk for hyperkalemia when aliskiren and ARBs or ACE inhibitors were used together[96] ; therefore, careful monitoring of serum potassium levels is warranted when these agents are used in combination.[96] Furthermore, in patients with hypertension and type 2 diabetes and renal impairment who are at high risk of cardiovascular and renal events, there is an increased risk of nonfatal stroke, renal complications, hypokalemia, and hypotension when aliskiren is added to ACE inhibitor or ARB therapy.

Losartan (Cozaar)

 

Losartan may be used alone or in combination with other antihypertensive agents, including diuretics. The initial dose is 50 mg daily; however, in patients on diuretic therapy, the initial dose is 25 mg daily. A low-dose diuretic (eg, hydrochlorothiazide) may be added if blood pressure is not controlled. Losartan can be titrated up to 100 mg daily.

Valsartan (Diovan)

 

Valsartan is approved for the treatment of hypertension in adults and in children 6-16 years of age. It may be used alone or in combination with other antihypertensive agents. The initial dose is 80 or 160 mg once daily when used as monotherapy in patients who are not volume depleted. The valsartan dose may be increased (maximum 320 mg/day), or a diuretic may be added if additional blood pressure reduction is required. The addition of a diuretic has a greater effect than dose increases above 80 mg.

Olmesartan (Benicar)

 

Olmesartan is indicated for hypertension either alone or in combination with other antihypertensives. The initial dose is 20 mg daily when used as monotherapy. The dose may be titrated to 40 mg daily if greater effect is desired. Doses greater than 40 mg have not been shown to have greater effects. If monotherapy is not sufficient, adding a diuretic should be considered.

Eprosartan (Teveten)

 

Eprosartan may be used alone or in combination with other antihypertensives, such as diuretics and calcium channel blockers. The initial dose is 600 mg once daily when used as monotherapy in patients who are not volume depleted. The dose may be titrated if clinical response is not sufficient. The usual dosage range is 400-800 mg once or twice daily.

Azilsartan (Edarbi)

 

Azilsartan is indicated for hypertension, either alone or in combination with other antihypertensives. The usual dose is 80 mg once daily. Consider starting with an initial dose of 40 mg once daily in patients receiving high-dose diuretics.

Previous
Next

Beta-Blockers, Beta-1 Selective

Class Summary

Beta-blockers are generally not recommended as first-line agents for the treatment of hypertension; however, they are suitable alternatives when a compelling cardiac indication (eg, heart failure, myocardial infarction, diabetes) is present. Selective beta-blockers specifically block beta-1 receptors alone, although they can be nonselective at higher doses.

Caution should be used in administering these agents in the setting of asthma or severe chronic obstructive pulmonary disease (COPD), regardless of beta-selectivity profile. In addition, exacerbations of angina and, in some cases, myocardial infarction have been reported following abrupt discontinuance of beta-blocker therapy. The doses should be gradually reduced over at least a few weeks.

Atenolol (Tenormin)

 

Atenolol is approved for the management of hypertension used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. The initial dose is 50 mg daily, alone or added to diuretic therapy. If adequate clinical effect is not seen, the dose can be titrated to 100 mg daily. Other studies suggest that atenolol lacks specific potential for stroke reduction.

Metoprolol (Lopressor, Toprol XL)

 

Metoprolol is approved for the management of hypertension alone or concomitantly with other antihypertensive agents. The initial dose for metoprolol immediate release is 100 mg daily in single or divided doses, with or without a diuretic (maximum 450 mg/day). Metoprolol extended-release formulation can be started at a dose of 25-100 mg daily in a single dose, with or without a diuretic (maximum 400 mg/day).

Propranolol (Inderal LA, InnoPran XL)

 

Propranolol is approved for the management of hypertension alone or concomitantly with other antihypertensive agents. The initial dose is 40 mg given twice daily, alone or added to diuretic therapy. Dose can be titrated based on a patient's clinical response. The maintenance dose can range from 120-240 mg/day (maximum 640 mg/day). Exacerbations of angina and, in some cases, myocardial infarction, following abrupt discontinuance of propranolol therapy have been reported. The propranolol dose should be gradually reduced over at least a few weeks.

Bisoprolol (Zebeta)

 

Bisoprolol is approved for the management of hypertension alone or in combination with other antihypertensive agents. This agent is a more specific beta-1 blocker than other beta-blockers. The initial dose is 5 mg once daily (reduce to 2.5 mg for patients with bronchospastic disease). The dosage can be titrated to 10 mg/day and then to 20 mg/day if necessary.

Timolol

 

Timolol is indicated for the treatment of hypertension. It is used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The initial dose is 10 mg given twice daily. The total daily dose can be titrated to a maximum of 30 mg administered in divided doses. Avoid abrupt cessation of therapy, because of the risk of exacerbation of ischemic heart disease.

Previous
Next

Beta-Blockers, Alpha Activity

Class Summary

Beta-blockers, such as labetalol and carvedilol, have peripheral vasodilatory effects that act via antagonism of the alpha-1 receptor in addition to beta-receptors.

Labetalol (Trandate)

 

Labetalol is indicated for the management of hypertension. Labetalol tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. The initial dose is 100 mg given twice daily. The dose may be titrated after 2-3 days in increments of 100 mg twice a day every 2-3 days (maximum 2400 mg/day).

Labetalol's actions at alpha-1 and beta-receptors lead to vasodilation and decreased total peripheral resistance, which results in decreased blood pressure without a substantial decrease in resting heart rate, cardiac output, or stroke volume.

Carvedilol (Coreg, Coreg CR)

 

Carvedilol is approved for the management of essential hypertension. It can be used as monotherapy or in combination with other antihypertensive agents, especially thiazide-type diuretics. The initial dose is 6.25 mg given twice daily. The dose can be titrated at intervals of 7-14 days to 12.5 mg twice daily, then to 25 mg twice daily as needed (maximum 50 mg/day).

Similar to labetalol, carvedilol antagonizes both alpha-1 and beta-receptors. Carvedilol lowers standing blood pressure more than supine blood pressure; orthostatic hypotension may occur.

Previous
Next

Beta-Blockers, Intrinsic Sympathomimetic

Class Summary

Agents such as acebutolol and pindolol possess intrinsic sympathomimetic activity (ISA). These agents can be used alone or in combination with other antihypertensive agents, particularly with a thiazide-type diuretic.

Acebutolol (Sectral)

 

Acebutolol is a cardioselective, beta-adrenoreceptor-blocking agent, which possesses mild intrinsic sympathomimetic activity in its therapeutically effective dose range. Initial dose in uncomplicated, mild to moderate hypertension is 400 mg daily, or twice-daily dosing may be required for adequate 24-hour blood pressure control. Optimal response is usually achieved with dosages of 400 to 800 mg/day; however, some patients have been maintained on as little as 200 mg/day.

Pindolol

 

Pindolol is indicated in the management of hypertension and can be used alone or with other antihypertensive agents, particularly with a thiazide-type diuretic. The initial dose is 5 mg twice daily alone or in combination with other antihypertensive agents. An antihypertensive response usually occurs within the first week of treatment. Maximal response, however, may take as long as 2 weeks or even longer.

Previous
Next

Vasodilators

Class Summary

Vasodilators relax blood vessels to improve blood flow, thus decreasing blood pressure.

Hydralazine

 

Oral hydralazine is indicated for essential hypertension, alone or as an adjunct. Initial dose is 10 mg given 4 times daily for the first 2 to 4 days, then 25 mg 4 times a day for 1 week. Hydralazine IV or IM is indicated for severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower BP. Hydralazine may lower blood pressure by exerting a peripheral, vasodilating effect through a direct relaxation of vascular smooth muscle. Caution should be used when hydralazine is administered in patients with concomitant coronary artery disease.

Minoxidil

 

Minoxidil is indicated in severe hypertension that is symptomatic or associated with end-organ damage and is not manageable with maximum therapeutic doses of a diuretic plus 2 other antihypertensives. The initial dose is 5 mg/day as a single dose and can be titrated to 10, 20, and then 40 mg in single or divided doses as needed (maximum 100 mg/day). Minoxidil reduces elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. The blood pressure response to minoxidil is dose-related and proportional to the extent of hypertension. Concomitant therapy with an antiadrenergic agent and loop diuretic is generally required.

Previous
Next

Calcium Channel Blockers

Class Summary

Calcium channel blockers (CCBs) can be divided into dihydropyridines and nondihydropyridines. Dihydropyridines bind to L-type calcium channels in the vascular smooth muscle, which results in vasodilatation and a decrease in blood pressure. They are effective as monotherapy in black patients and elderly patients. Some examples of dihydropyridines include amlodipine, nifedipine, clevidipine, and felodipine. Non-dihydropyridines such as verapamil and diltiazem bind to L-type calcium channels in the sinoatrial and atrioventricular node, as well as exerting effects in the myocardium and vasculature. These agents may constitute a more effective class of medication for black patients.[97]

Nifedipine (Adalat CC, Afeditab CR, Nifediac CC, Nifedical XL, Procardia XL)

 

Nifedipine extended-release is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. The usual dose for nifedipine is 30-60 mg once daily (maximum 90 mg/day); when used for hypertension, nifedipine can be administered to a maximum of 120 mg/day.

Clevidipine (Cleviprex)

 

Clevidipine butyrate is a dihydropyridine L-type CCB that is rapidly metabolized in blood and tissues and does not accumulate in the body. L-type calcium channels mediate the influx of calcium during depolarization in arterial smooth muscle. It is indicated for the reduction of BP when oral therapy is not feasible or is not desirable.

Amlodipine (Norvasc)

 

Amlodipine is a dihydropyridine CCB that has antianginal and antihypertensive effects. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.

Felodipine (Plendil)

 

Felodipine is a dihydropyridine CCB that inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes. These effects elicit an increased oxygen delivery to the myocardial tissue, a decreased total peripheral resistance, a decreased systemic blood pressure, and a decreased afterload.

Diltiazem (Cardizem CD, Cardizem LA, Cartia XT, Dilacor XR, Dilt-CD, Dilt-XR, Matzim LA, Taztia XT, Tiazac)

 

Diltiazem is a nondihydropyridine CCB that produces its antihypertensive effect primarily by relaxation of vascular smooth muscle and the resultant decrease in peripheral vascular resistance. The magnitude of blood pressure reduction is related to the degree of hypertension.

Verapamil (Calan, Calan SR, Covera-HS, Isoptin SR, Verelan, Verelan PM)

 

Verapamil is a nondihydropyridine that produces its antihypertensive effect by a combination of vascular and cardiac effects. It acts as a vasodilator with selectivity for the arterial portion of the peripheral vasculature. As a result, the systemic vascular resistance is reduced, usually without orthostatic hypotension or reflex tachycardia.

Previous
Next

Aldosterone Antagonists, Selective

Class Summary

Aldosterone antagonists compete with aldosterone receptor sites, reducing blood pressure and sodium reabsorption.

Eplerenone (Inspra)

 

Eplerenone selectively blocks aldosterone at the mineralocorticoid receptors in epithelial (eg, kidney) and nonepithelial (eg, heart, blood vessels, brain) tissues, thus decreasing BP and sodium reabsorption. Although this agent is more specific than spironolactone at the mineralocorticoid receptor, it is less potent. There have also been some minimal reports of gynecomastia.

Eplerenone is indicated for the treatment of hypertension. Eplerenone may be used alone or in combination with other antihypertensive agents.

Spironolactone

 

Spironolactone is usually used in combination with other drugs for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. The initial dose ranges from 50-100 mg daily in single or divided doses. Spironolactone can cause hyperkalemia; therefore, potassium supplementation should not be given concurrently. Other adverse effects include gynecomastia and impotence, which often mitigates the use of spironolactone in younger men.

Previous
Next

Alpha2-agonists, Central-acting

Class Summary

Centrally acting alpha2-agonists stimulate presynaptic alpha2-adrenergic receptors in the brain stem, which reduces sympathetic nervous activity.

Methyldopa

 

Methyldopa stimulates central alpha-adrenergic receptors by a false transmitter, exerting a direct effect on peripheral sympathetic nerves. Decreases in blood pressure are greatest when the patient is standing but are also significant when the patient is supine. Postural hypotension has been reported in patients receiving methyldopa. Methyldopa is not associated with a rebound effect, as with clonidine.

Clonidine (Catapres)

 

Clonidine stimulates alpha2-adrenoreceptors in the brain stem, activating an inhibitory neuron, which in turn results in reduced sympathetic outflow. These effects result in a decrease in peripheral resistance, renal vascular resistance, blood pressure, and heart rate. Clonidine can be used alone or in combination with other antihypertensives. Clonidine is associated with a rebound effect, especially at higher doses or with more severe hypertension.

Guanfacine (Tenex)

 

Guanfacine is an orally active antihypertensive agent whose principal mechanism of action appears to be stimulation of central alpha-2 adrenergic receptors. By stimulating these receptors, guanfacine reduces sympathetic nerve impulses from the vasomotor center to the heart and blood vessels. This results in a decrease in peripheral vascular resistance and a reduction in heart rate. Guanfacine may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

Previous
Next

Renin Inhibitors/Combos

Class Summary

Renin inhibitors act within the renin-angiotensin system (RAS), a hormone system important in the regulation of blood pressure, electrolyte homeostasis, and vascular growth. Renin inhibitors have an additive effect when used with diuretics. Avoid the use of these agents in pregnancy.

Aliskiren (Tekturna)

 

Aliskiren decreases plasma renin activity and inhibits conversion of angiotensinogen to angiotensin I (as a result, also decreasing angiotensin II) and thereby disrupts the renin-angiotensin-aldosterone system feedback loop. It is indicated for hypertension as monotherapy or in combination with other antihypertensive drugs. This agent remains under investigation.

Keep in mind that aliskiren can cause adverse events when used in combination with ACE-inhibitor or angiotensin-receptor-blocker (ARB) therapy. In patients who have hypertension and type 2 diabetes and renal impairment and are at high risk of cardiovascular and renal events, there is an increased risk of nonfatal stroke, renal complications, hypokalemia, and hypotension when aliskiren is added to ACE inhibitor or ARB therapy. See the Novartis December 2011 press release, "Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in high-risk patients with diabetes and renal impairment."

Previous
Next

Alpha-Blockers, Antihypertensives

Class Summary

Alpha-blockers are generally not recommended as initial monotherapy. They selectively block postsynaptic alpha1 -adrenergic receptors. They dilate arterioles and veins, thus lowering blood pressure. These drugs can be combined with any of the other antihypertensives in other drug classes. Common side effects seen in this drug class include dizziness, headache, and drowsiness, in addition to orthostatic and first-dose hypotension.

Prazosin (Minipress)

 

Prazosin is a competitive antagonist at postsynaptic alpha1-receptors. Prazosin causes peripheral vasodilation by selective, competitive inhibition of vascular postsynaptic alpha1-adrenergic receptors, thus reducing peripheral vascular resistance and blood pressure.

Terazosin

 

Terazosin causes peripheral vasodilation by selective, competitive inhibition of vascular postsynaptic alpha1-adrenergic receptors, thereby reducing peripheral vascular resistance and blood pressure. Terazosin reduces blood pressure in both the supine and the standing positions, with more dramatic effects on diastolic blood pressure.

Doxazosin (Cardura, Cardura XL)

 

Doxazosin is a selective alpha1-adrenergic antagonist. It inhibits postsynaptic alpha-adrenergic receptors, resulting in vasodilation of veins and arterioles and a decrease in total peripheral resistance and blood pressure. The antihypertensive effect of doxazosin mesylate results from a decrease in systemic vascular resistance.

Previous
Next

Antihypertensives, Other

Class Summary

Reserpine is a peripherally acting adrenergic agent. It is indicated for mild hypertension and can be used as adjunctive therapy with other antihypertensive agents in more severe forms of hypertension.

Reserpine

 

Reserpine reduces blood pressure by depleting sympathetic biogenic amines. The result of reserpine's effects on biogenic amines is sympathetic dysfunction, with a subsequent decrease in peripheral vascular resistance and a lowering of blood pressure often associated with bradycardia. This agent is also associated with depression.

Previous
Next

Antihypertensive Combinations

Class Summary

Drug combinations using agents that act by different mechanisms have an additive effect. Most clinicians recommend initiating therapy with a single agent and advancing to the low-dose combination therapy. Some patients will require multiple medications to achieve their blood pressure targets and will benefit from drug combinations. Drug combination therapy may also help to improve patient compliance.

Drug combinations include—but are not limited to—the following:

- Amlodipine/benazepril (Lotrel)

- Amlodipine/olmesartan (Azor)

- Amlodipine/telmisartan (Twynsta)

- Amlodipine/valsartan (Exforge)

- Amlodipine/valsartan/hydrochlorothiazide (Exforge HCT)

- Amlodipine/aliskiren (Tekamlo)

- Amlodipine/aliskiren/hydrochlorothiazide (Amturnide)

- Olmesartan/amlodipine/hydrochlorothiazide (Tribenzor)

- Trandolapril/verapamil (Tarka)

- Benazepril/hydrochlorothiazide (Lotensin HCT)

- Captopril/hydrochlorothiazide (Capozide)

- Enalapril/hydrochlorothiazide (Vaseretic)

- Fosinopril/hydrochlorothiazide

- Lisinopril/hydrochlorothiazide (Prinzide, Zestoretic)

- Moexipril/hydrochlorothiazide (Uniretic)

- Quinapril/hydrochlorothiazide (Accuretic)

- Candesartan/hydrochlorothiazide (Atacand HCT)

- Eprosartan/hydrochlorothiazide (Teveten HCT)

- Irbesartan/hydrochlorothiazide (Avalide)

- Losartan/hydrochlorothiazide (Hyzaar)

- Olmesartan/hydrochlorothiazide (Benicar HCT)

- Telmisartan/hydrochlorothiazide (Micardis HCT)

- Valsartan/hydrochlorothiazide (Diovan HCT)

- Atenolol/chlorthalidone (Tenoretic)

- Bisoprolol/hydrochlorothiazide (Ziac)

- Metoprolol/hydrochlorothiazide (Lopressor HCT)

- Nadolol/bendroflumethiazide (Corzide)

- Propranolol/hydrochlorothiazide

- Aliskiren/hydrochlorothiazide (Tekturna HCT)

- Clonidine/chlorthalidone (Clorpres)

- Spironolactone/hydrochlorothiazide (Aldactazide)

- Triamterene/hydrochlorothiazide (Dyazide, Maxzide)

- Methyldopa/hydrochlorothiazide

- Amiloride/hydrochlorothiazide

Metoprolol/hydrochlorothiazide (Lopressor HCT)

 

Metoprolol/hydrochlorothiazide is a combination of metoprolol, a beta-blocker, and hydrochlorothiazide, a thiazide diuretic. Metoprolol is a beta1-selective blocker at low doses; at higher doses, it also inhibits beta2-adrenoreceptors. Hydrochlorothiazide inhibits sodium reabsorption in distal renal tubules, resulting in increased excretion of water, sodium, potassium, and hydrogen ions.

Triamterene/hydrochlorothiazide (Maxzide, Maxzide-25, Dyazide)

 

Triamterene/hydrochlorothiazide is a fixed-combination indicated for hypertension or edema in patients who are at risk of developing hypokalemia on hydrochlorothiazide alone. Triamterene exerts a diuretic effect on the distal renal tubule, inhibiting the reabsorption of sodium in exchange for potassium and hydrogen ions. Hydrochlorothiazide inhibits sodium and chloride reabsorption in distal renal tubules, resulting in increased excretion of water, sodium, potassium, and hydrogen ions.

Valsartan/hydrochlorothiazide (Diovan HCT)

 

Valsartan/hydrochlorothiazide is a combination of valsartan, an angiotensin receptor blocker, and hydrochlorothiazide, a diuretic. Valsartan is a prodrug that produces direct antagonism of angiotensin II receptors. It displaces angiotensin II from AT1 receptor and may lower blood pressure by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. Hydrochlorothiazide inhibits sodium and chloride reabsorption in distal renal tubules, resulting in increased excretion of water, sodium, potassium, and hydrogen ions.

Valsartan/amlodipine/hydrochlorothiazide (Exforge HCT)

 

Valsartan/amlodipine/hydrochlorothiazide is a combination of amlodipine, a dihydropyridine calcium channel blocker, valsartan, an angiotensin receptor blocker, and hydrochlorothiazide, a diuretic. Amlodipine exhibits antianginal and antihypertensive effects by inhibiting the influx of calcium in cardiac and smooth muscle cells of the coronary and peripheral vasculature, resulting in dilatation of coronary and peripheral arteries. Valsartan is a prodrug that produces direct antagonism of angiotensin II receptors. It displaces angiotensin II from the AT1 receptor and may lower blood pressure by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. Hydrochlorothiazide inhibits sodium and chloride reabsorption in distal renal tubules, resulting in increased excretion of water, sodium, potassium, and hydrogen ions.

Enalapril/hydrochlorothiazide (Vaseretic)

 

Enalapril/hydrochlorothiazide is a combination of enalapril, an ACE inhibitor, and hydrochlorothiazide, a diuretic. Hydrochlorothiazide inhibits sodium reabsorption in distal renal tubules, resulting in increased excretion of water, sodium, potassium, and hydrogen ions. Enalapril prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, resulting in increased levels of plasma renin and a reduction in aldosterone secretion. It helps control blood pressure and proteinuria.

Azilsartan/chlorthalidone (Edarbyclor)

 

This is an angiotensin II receptor blocker (ARB) and thiazide-like diuretic combination. It is indicated as initial hypertension therapy or for the treatment of hypertension in patients whose condition is not adequately controlled with monotherapy.

Previous
 
Contributor Information and Disclosures
Author

Meena S Madhur, MD, PhD Assistant Professor, Department of Medicine, Divisions of Clinical Pharmacology and Cardiology, Vanderbilt University School of Medicine

Meena S Madhur, MD, PhD is a member of the following medical societies: American College of Cardiology, American Heart Association

Disclosure: Nothing to disclose.

Coauthor(s)

Kamran Riaz, MD Clinical Assistant Professor, Department of Internal Medicine, Section of Cardiology, Wright State University, Boonshoft School of Medicine

Kamran Riaz, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Society of Echocardiography, Ohio State Medical Association, Royal College of Physicians

Disclosure: Nothing to disclose.

Albert W Dreisbach, MD Associate Professor of Medicine, Division of Nephrology, University of Mississippi Medical Center

Disclosure: Nothing to disclose.

David G Harrison, MD Betty and Jack Bailey Professor of Medicine and Pharmacology, Director of Clinical Pharmacology, Vanderbilt University School of Medicine

David G Harrison, MD is a member of the following medical societies: American College of Cardiology, American Heart Association, American Physiological Society, American Society for Clinical Investigation, Association of American Physicians, Central Society for Clinical and Translational Research, American Federation for Clinical Research, Society for Vascular Medicine

Disclosure: Nothing to disclose.

Chief Editor

David J Maron, MD, FACC, FAHA Clinical Professor of Medicine (Cardiovascular), Director, Preventive Cardiology, ISCHEMIA Trial Co-Chair/PI, Stanford University School of Medicine

David J Maron, MD, FACC, FAHA is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association

Disclosure: Received ownership interest from Cardiovascular Care Group for other.

Acknowledgements

George R Aronoff, MD Director, Professor, Departments of Internal Medicine and Pharmacology, Section of Nephrology, Kidney Disease Program, University of Louisville School of Medicine

George R Aronoff, MD is a member of the following medical societies: American Federation for Medical Research, American Society of Nephrology, Kentucky Medical Association, and National Kidney Foundation

Disclosure: Nothing to disclose.

Michael S Beeson, MD, MBA, FACEP Professor of Emergency Medicine, Northeastern Ohio Universities College of Medicine and Pharmacy; Attending Faculty, Akron General Medical Center

Michael S Beeson, MD, MBA, FACEP is a member of the following medical societies: American College of Emergency Physicians, Council of Emergency Medicine Residency Directors, National Association of EMS Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Pamela L Dyne, MD Professor of Clinical Medicine/Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine; Attending Physician, Department of Emergency Medicine, Olive View-UCLA Medical Center

Pamela L Dyne, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Mert Erogul, MD Assistant Professor of Emergency Medicine, University Hospital of Brooklyn: Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Mert Erogul, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Allysia M Guy, MD Staff Physician, Department of Emergency Medicine, State University of New York Downstate Medical Center

Disclosure: Nothing to disclose.

Dawn C Jung, MD Staff Physician, Department of Emergency Medicine, Suny Downstate Medical Center, Kings County Hospital Center

Dawn C Jung, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Claude Kortas, MD, MEd, FRCP(C) Program Director, Associate Professor, Department of Medicine, University of Western Ontario, Canada

Claude Kortas, MD, Med, FRCP(C) is a member of the following medical societies: American Society of Nephrology, College of Physicians and Surgeons of Ontario, Ontario Medical Association, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Stephen C Morris, MD Resident, Section of Emergency Medicine, Department of Surgery, Yale New Haven Hospital

Stephen C Morris, MD is a member of the following medical societies: American College of Emergency Physicians and American Medical Association

Disclosure: Nothing to disclose.

L Michael Prisant, MD, FACC, FAHA Cardiologist, Emeritus Professor of Medicine, Medical College of Georgia

L Michael Prisant, MD, FACC, FAHA is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American College of Clinical Pharmacology, American College of Forensic Examiners, American College of Physicians, American Heart Association, and American Medical Association

Disclosure: Boehringer-Ingelheim Honoraria Speaking and teaching

Assaad J Sayah, MD Chief, Department of Emergency Medicine, Cambridge Health Alliance

Assaad J Sayah, MD is a member of the following medical societies: National Association of EMS Physicians

Disclosure: Nothing to disclose.

Zina Semenovskaya, MD Resident Physician, Department of Emergency Medicine, Kings County Hospital, State University of New York Downstate Medical Center College of Medicine

Disclosure: Nothing to disclose.

Sat Sharma, MD, FRCPC Professor and Head, Division of Pulmonary Medicine, Department of Internal Medicine, University of Manitoba; Site Director, Respiratory Medicine, St Boniface General Hospital

Sat Sharma, MD, FRCPC is a member of the following medical societies: American Academy of Sleep Medicine, American College of Chest Physicians, American College of Physicians-American Society of Internal Medicine, American Thoracic Society, Canadian Medical Association, Royal College of Physicians and Surgeons of Canada, Royal Society of Medicine, Society of Critical Care Medicine, and World Medical Association

Disclosure: Nothing to disclose.

Mark A Silverberg, MD, MMB, FACEP Assistant Professor, Associate Residency Director, Department of Emergency Medicine, State University of New York Downstate College of Medicine; Consulting Staff, Department of Emergency Medicine, Staten Island University Hospital, Kings County Hospital, University Hospital, State University of New York Downstate Medical Center

Mark A Silverberg, MD, MMB, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Council of Emergency Medicine Residency Directors, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Mark Zwanger, MD, MBA Assistant Professor, Department of Emergency Medicine, Jefferson Medical College of Thomas Jefferson University

Mark Zwanger, MD, MBA is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and American Medical Association

Disclosure: Nothing to disclose.

References
  1. Harrison L. Hypertension ER Visits Surge 25% in Five Years. Medscape. Sep 11 2014. [Full Text].

  2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. 2012 Jan 3. 125(1):e2-e220. [Medline].

  3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec. 42(6):1206-52. [Medline].

  4. Katakam R, Brukamp K, Townsend RR. What is the proper workup of a patient with hypertension?. Cleve Clin J Med. 2008 Sep. 75(9):663-72. [Medline].

  5. Institute for Clinical Systems Improvement (ICSI). Hypertension diagnosis and treatment. Bloomington, Minn: Institute for Clinical Systems Improvement (ICSI); 2010.

  6. Whelton PK, Appel LJ, Sacco RL, Anderson CA, Antman EM, Campbell N, et al. Sodium, Blood Pressure, and Cardiovascular Disease: Further Evidence Supporting the American Heart Association Sodium Reduction Recommendations. Circulation. 2012 Nov 2. [Medline].

  7. O'Riordan M. New European Hypertension Guidelines Released: Goal Is Less Than 140 mm Hg for All. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/806367. Accessed: June 24, 2013.

  8. [Guideline] Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. 23rd European Meeting on Hypertension & Cardiovascular Protection. Available at http://www.esh2013.org/wordpress/wp-content/uploads/2013/06/ESC-ESH-Guidelines-2013.pdf. Accessed: June 24, 2013.

  9. [Guideline] James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013 Dec 18. [Medline]. [Full Text].

  10. Wood S. JNC 8 at last! Guidelines ease up on BP thresholds, drug choices. Heartwire. December 18, 2013. [Full Text].

  11. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003 Jul 9. 290(2):199-206. [Medline].

  12. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis. 1999 Dec. 34(6):973-95. [Medline].

  13. Shayne PH, Pitts SR. Severely increased blood pressure in the emergency department. Ann Emerg Med. 2003 Apr. 41(4):513-29. [Medline].

  14. Rhoades R, Planzer R. Human Physiology. 3rd. Fort Worth, TX: Saunders College Publishing; 1996.

  15. Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001 Jan 4. 344(1):17-22. [Medline].

  16. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011 Feb. 57(2):132-40. [Medline]. [Full Text].

  17. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007 Oct 1. 204(10):2449-60. [Medline].

  18. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010 Feb. 55(2):500-7. [Medline].

  19. Hamer M, Steptoe A. Cortisol responses to mental stress and incident hypertension in healthy men and women. J Clin Endocrinol Metab. 2012 Jan. 97(1):E29-34. [Medline].

  20. Rule AD, Fridley BL, Hunt SC, Asmann Y, Boerwinkle E, Pankow JS, et al. Genome-wide linkage analysis for uric acid in families enriched for hypertension. Nephrol Dial Transplant. 2009 Aug. 24(8):2414-20. [Medline]. [Full Text].

  21. Jermendy G, Horvath T, Littvay L, et al. Effect of genetic and environmental influences on cardiometabolic risk factors: a twin study. Cardiovasc Diabetol. 2011 Nov 3. 10:96. [Medline]. [Full Text].

  22. Mitchell GF, DeStefano AL, Larson MG, et al. Heritability and a genome-wide linkage scan for arterial stiffness, wave reflection, and mean arterial pressure: the Framingham Heart Study. Circulation. 2005 Jul 12. 112(2):194-9. [Medline].

  23. Levy D, DeStefano AL, Larson MG, et al. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. Hypertension. 2000 Oct. 36(4):477-83. [Medline].

  24. Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med. 2011 Nov 7. 17(11):1402-9. [Medline].

  25. Millis RM. Epigenetics and hypertension. Curr Hypertens Rep. 2011 Feb. 13(1):21-8. [Medline].

  26. Brown MJ. Hypertension and ethnic group. BMJ. 2006 Apr 8. 332(7545):833-6. [Medline]. [Full Text].

  27. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. STUDIES ON EXPERIMENTAL HYPERTENSION : I. THE PRODUCTION OF PERSISTENT ELEVATION OF SYSTOLIC BLOOD PRESSURE BY MEANS OF RENAL ISCHEMIA. J Exp Med. 1934 Feb 28. 59(3):347-79. [Medline]. [Full Text].

  28. Silverberg DS, Iaina A, Oksenberg A. Treating obstructive sleep apnea improves essential hypertension and quality of life. Am Fam Physician. 2002 Jan 15. 65(2):229-36. [Medline].

  29. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007 Jun. 131(6):1949-62. [Medline].

  30. Rodriguez MA, Kumar SK, De Caro M. Hypertensive crisis. Cardiol Rev. 2010 Mar-Apr. 18(2):102-7. [Medline].

  31. Hollander JE. Cocaine intoxication and hypertension. Ann Emerg Med. 2008 Mar. 51(3 Suppl):S18-20. [Medline].

  32. Qureshi AI, Suri MF, Kirmani JF, Divani AA. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit. 2005 Sep. 11(9):CR403-9. [Medline].

  33. Catalá-López F, Sanfélix-Gimeno G, García-Torres C, Ridao M, Peiró S. Control of arterial hypertension in Spain: a systematic review and meta-analysis of 76 epidemiological studies on 341?632 participants. J Hypertens. 2012 Jan. 30(1):168-76. [Medline].

  34. Cornoni-Huntley J, LaCroix AZ, Havlik RJ. Race and sex differentials in the impact of hypertension in the United States. The National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med. 1989 Apr. 149(4):780-8. [Medline].

  35. Strong Heart Study Data Book: A Report to American Indian Communities. Bethesda, MD: National Heart, Lung, and Blood Institute, NIH; 2001.

  36. Ong YT, Wong TY, Klein R, Klein BE, Mitchell P, Sharrett AR, et al. Hypertensive Retinopathy and Risk of Stroke. Hypertension. 2013 Aug 12. [Medline].

  37. Brooks M. Hypertensive Retinopathy Linked to Increased Stroke Risk. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/809541. Accessed: August 20, 2013.

  38. Huang Y, Cai X, Li Y, et al. Prehypertension and the risk of stroke: a meta-analysis. Neurology. 2014 Mar 12. [Medline].

  39. Hughes S. Even prehypertension increases stroke risk: meta-analysis. Medscape Medical News. March 14, 2014. [Full Text].

  40. Webster J, Petrie JC, Jeffers TA, Lovell HG. Accelerated hypertension--patterns of mortality and clinical factors affecting outcome in treated patients. Q J Med. 1993 Aug. 86(8):485-93. [Medline].

  41. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999 Jul 6. 131(1):7-13. [Medline].

  42. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990 Nov. 82(5):1616-28. [Medline].

  43. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011 May. 57(5):891-7. [Medline].

  44. Ford ES. Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States. Circulation. 2011 Apr 26. 123(16):1737-44. [Medline].

  45. Bombelli M, Facchetti R, Sega R, Carugo S, Fodri D, Brambilla G, et al. Impact of body mass index and waist circumference on the long-term risk of diabetes mellitus, hypertension, and cardiac organ damage. Hypertension. 2011 Dec. 58(6):1029-35. [Medline].

  46. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension. 1998 Feb. 31(2):712-8. [Medline].

  47. Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med. 2004 Nov 25. 351(22):2310-7. [Medline].

  48. Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P. Hypertensive urgencies and emergencies. Prevalence and clinical presentation. Hypertension. 1996 Jan. 27(1):144-7. [Medline].

  49. Staykov D, Schwab S. Posterior reversible encephalopathy syndrome. J Intensive Care Med. 2012 Feb. 27(1):11-24. [Medline].

  50. McCord J, Mundy BJ, Hudson MP, Maisel AS, Hollander JE, Abraham WT. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med. 2004 Nov 8. 164(20):2247-52. [Medline].

  51. Wang IK, Muo CH, Chang YC, Liang JC, Chang CT, Lin SY, et al. Association between hypertensive disorders during pregnancy and end-stage renal disease: a population-based study. CMAJ. 2013 Jan 21. [Medline].

  52. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25. 112(17):2735-52. [Medline].

  53. Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension?. JAMA. 1988 Jan 8. 259(2):225-8. [Medline].

  54. Stiles S. Framingham Criteria Predict New Hypertension Better Than Prehypertension in Young Adults. Medscape Medical News. Available at http://www.medscape.com/viewarticle/811416. Accessed: September 30, 2013.

  55. Carson AP, Lewis CE, Jacobs DR Jr, Peralta CA, Steffen LM, Bower JK, et al. Evaluating the Framingham Hypertension Risk Prediction Model in Young Adults: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Hypertension. 2013 Sep 16. [Medline].

  56. Olin JW, Piedmonte MR, Young JR, DeAnna S, Grubb M, Childs MB. The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. Ann Intern Med. 1995 Jun 1. 122(11):833-8. [Medline].

  57. US Food and Drug Administration. Information on gadolinium-based contrast agents. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142882.htm. Accessed: February 22, 2012.

  58. Cortigiani L, Bigi R, Landi P, Bovenzi F, Picano E, Sicari R. Prognostic implication of stress echocardiography in 6214 hypertensive and 5328 normotensive patients. Eur Heart J. 2011 Jun. 32(12):1509-18. [Medline].

  59. O'Riordan M. AHA/ACC/CDC Issue 'Science Advisory' on Treating BP. Medscape. Nov 15 2013. [Full Text].

  60. [Guideline] Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2013 Nov 15. [Medline]. [Full Text].

  61. [Guideline] American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care. 2011 Jan. 34 Suppl 1:S11-61. [Medline]. [Full Text].

  62. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, Erdine S, et al. Mechanisms of hypertension in the cardiometabolic syndrome. J Hypertens. 2009 Mar. 27(3):441-51. [Medline].

  63. Forman JP, Scheven L, de Jong PE, Bakker SJ, Curhan GC, Gansevoort RT. Association between sodium intake and change in uric acid, urine albumin excretion, and the risk of developing hypertension. Circulation. 2012 Jun 26. 125(25):3108-16. [Medline].

  64. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ. 2013 Apr 3. [Medline].

  65. Ried K, Sullivan T, Fakler P, Frank OR, Stocks NP. Does chocolate reduce blood pressure? A meta-analysis. BMC Med. 2010 Jun 28. 8:39. [Medline]. [Full Text].

  66. Egan BM, Laken MA, Donovan JL, Woolson RF. Does dark chocolate have a role in the prevention and management of hypertension?: commentary on the evidence. Hypertension. 2010 Jun. 55(6):1289-95. [Medline].

  67. Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2006 Apr 19. CD005182. [Medline].

  68. Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010 Jan 25. 170(2):126-35. [Medline].

  69. Boggs W. Benazepril plus amlodipine effective for high-risk, stage 2 hypertension. Medscape Medical News. May 3, 2013. [Full Text].

  70. Bakris G, Briasoulis A, Dahlof B, Jamerson K, Weber MA, Kelly RY, et al. Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease. Am J Cardiol. 2013 Apr 11. [Medline].

  71. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 4. 359(23):2417-28. [Medline].

  72. Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension. 2011 Nov. 58(5):776-83. [Medline].

  73. O'Riordan M. Spironolactone Provides Benefit in Resistant Hypertension, Small Study Shows. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/806388. Accessed: July 29, 2013.

  74. Pancioli AM. Hypertension management in neurologic emergencies. Ann Emerg Med. 2008 Mar. 51(3 Suppl):S24-7. [Medline].

  75. Slovis CM, Reddi AS. Increased blood pressure without evidence of acute end organ damage. Ann Emerg Med. 2008 Mar. 51(3 Suppl):S7-9. [Medline].

  76. Blowey DL, Duda PJ, Stokes P, Hall M. Incidence and treatment of hypertension in the neonatal intensive care unit. J Am Soc Hypertens. 2011 Nov-Dec. 5(6):478-83. [Medline].

  77. Kostis JB, Cabrera J, Cheng JQ, Cosgrove NM, Deng Y, Pressel SL, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA. 2011 Dec 21. 306(23):2588-93. [Medline].

  78. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997 Sep 13. 350(9080):757-64. [Medline].

  79. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011 May 17. 57(20):2037-114. [Medline].

  80. Weinberger MH, Izzo JL Jr, Purkayastha D, Weitzman R, Black HR. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome. J Am Soc Hypertens. 2011 Nov-Dec. 5(6):489-97. [Medline].

  81. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003 Nov. 16(11 Pt 1):925-30. [Medline].

  82. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011 May. 57(5):898-902. [Medline].

  83. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009 Apr 11. 373(9671):1275-81. [Medline].

  84. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011 May. 57(5):911-7. [Medline].

  85. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010 Dec 4. 376(9756):1903-9. [Medline].

  86. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011 Aug 9. 58(7):765-73. [Medline].

  87. de La Sierra A, Larrousse M, Oliveras A, Armario P, Hernández-Del Rey R, Poch E, et al. Abnormalities of vascular function in resistant hypertension. Blood Press. 2012 Apr. 21(2):104-9. [Medline].

  88. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011 Apr 19. 123(15):1611-21. [Medline]. [Full Text].

  89. Fagugli RM, Taglioni C. Changes in the perceived epidemiology of primary hyperaldosteronism. Int J Hypertens. 2011. 2011:162804. [Medline]. [Full Text].

  90. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011 Nov. 58(5):811-7. [Medline].

  91. Martínez-Garcia MA, Capote F, Campos-Rodriguez F, et al, for the Spanish Sleep Network. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA. 2013 Dec 11. 310(22):2407-15. [Medline].

  92. O'Riordan M. CPAP reduces blood pressure in resistant hypertension. Heartwire. December 10, 2013. [Full Text].

  93. Pezzin LE, Feldman PH, Mongoven JM, McDonald MV, Gerber LM, Peng TR. Improving blood pressure control: results of home-based post-acute care interventions. J Gen Intern Med. 2011 Mar. 26(3):280-6. [Medline]. [Full Text].

  94. Bosworth HB, Powers BJ, Olsen MK, McCant F, Grubber J, Smith V, et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Intern Med. 2011 Jul 11. 171(13):1173-80. [Medline].

  95. Leung AA, Wright A, Pazo V, Karson A, Bates DW. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med. 2011 Nov. 124(11):1064-72. [Medline].

  96. Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, et al. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis. BMJ. 2012 Jan 9. 344:e42. [Medline]. [Full Text].

  97. Cummings DM, Amadio P Jr, Nelson L, Fitzgerald JM. The role of calcium channel blockers in the treatment of essential hypertension. Arch Intern Med. 1991 Feb. 151(2):250-9. [Medline].

  98. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999 Feb. 17(2):151-83. [Medline].

  99. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007 Jan 24. CD002252. [Medline].

  100. Abergel E, Chatellier G, Battaglia C, Menard J. Can echocardiography identify mildly hypertensive patients at high risk, left untreated based on current guidelines?. J Hypertens. 1999 Jun. 17(6):817-24. [Medline].

  101. AHRQ: Agency for Healthcare Research and Quality. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension. Agency for Healthcare Research and Quality. Available at http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=12%20&DocID=48. Accessed: May 14, 2009.

  102. American College of Radiology. Manual on Contrast Media. Vers. 7. Available at http://www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx. Accessed: February 22, 2012.

  103. Anderson CS, Huang Y, Arima H, Heeley E, Skulina C, Parsons MW, et al. Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT). Stroke. 2010 Feb. 41(2):307-12. [Medline].

  104. Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol. 2008 May. 7(5):391-9. [Medline].

  105. Ault MJ, Ellrodt AG. Pathophysiological events leading to the end-organ effects of acute hypertension. Am J Emerg Med. 1985 Dec. 3(6 Suppl):10-5. [Medline].

  106. Barton JR. Hypertension in pregnancy. Ann Emerg Med. 2008 Mar. 51(3 Suppl):S16-7. [Medline].

  107. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011 Jan 22. 377(9762):312-20. [Medline].

  108. Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke. 2004 Jan. 35(1):116-21. [Medline].

  109. Cheung AT, Hobson RW 2nd. Hypertension in vascular surgery: aortic dissection and carotid revascularization. Ann Emerg Med. 2008 Mar. 51(3 Suppl):S28-33. [Medline].

  110. Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med. 1996 Jan. 5(1):17-24; discussion 25. [Medline].

  111. Chrysant SG, Izzo JL Jr, Kereiakes DJ, Littlejohn T 3rd, Oparil S, Melino M, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens. 2012 Mar-Apr. 6(2):132-41. [Medline].

  112. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012 Aug. 60(2):310-8. [Medline].

  113. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29. 362(17):1575-85. [Medline].

  114. Daien V, Duny Y, Ribstein J, du Cailar G, Mimran A, Villain M, et al. Treatment of hypertension with renin-angiotensin system inhibitors and renal dysfunction: a systematic review and meta-analysis. Am J Hypertens. 2012 Jan. 25(1):126-32. [Medline].

  115. Diercks DB, Ohman EM. Hypertension with acute coronary syndrome and heart failure. Ann Emerg Med. 2008 Mar. 51(3 Suppl):S34-6. [Medline].

  116. Dungan JR, Conley YP, Langaee TY, Johnson JA, Kneipp SM, Hess PJ, et al. Altered beta-2 adrenergic receptor gene expression in human clinical hypertension. Biol Res Nurs. 2009 Jul. 11(1):17-26. [Medline]. [Full Text].

  117. Epstein M. Calcium antagonists and renal disease. Kidney Int. 1998 Nov. 54(5):1771-84. [Medline].

  118. Faselis C, Doumas M, Kokkinos JP, Panagiotakos D, Kheirbek R, Sheriff HM, et al. Exercise capacity and progression from prehypertension to hypertension. Hypertension. 2012 Aug. 60(2):333-8. [Medline].

  119. [Guideline] Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 Feb. 42(2):517-84. [Medline].

  120. Ha V, Sievenpiper JL, de Souza RJ, Chiavaroli L, Wang DD, Cozma AI, et al. Effect of fructose on blood pressure: a systematic review and meta-analysis of controlled feeding trials. Hypertension. 2012 Apr. 59(4):787-95. [Medline].

  121. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000 Jul 29. 356(9227):359-65. [Medline].

  122. Heilpern K. Pathophysiology of hypertension. Ann Emerg Med. 2008 Mar. 51(3 Suppl):S5-6. [Medline].

  123. Hermida RC, Ayala DE, Mojón A, Fernández JR. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol. 2011 Sep 6. 58(11):1165-73. [Medline].

  124. Izzo JL Jr, Weintraub HS, Duprez DA, Purkayastha D, Zappe D, Samuel R, et al. Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either monotherapy: ValVET primary results. J Clin Hypertens (Greenwich). 2011 Oct. 13(10):722-30. [Medline].

  125. Kandzari DE, Bhatt DL, Sobotka PA, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep. 35(9):528-35. [Medline].

  126. Kaplan NM. Calcium entry blockers in the treatment of hypertension. Current status and future prospects. JAMA. 1989 Aug 11. 262(6):817-23. [Medline].

  127. Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW, et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol. 2005 Jun. 21(8):657-72. [Medline].

  128. Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol. 1998 Jan. 9(1):133-42. [Medline].

  129. Lao D, Parasher PS, Cho KC, Yeghiazarians Y. Atherosclerotic renal artery stenosis--diagnosis and treatment. Mayo Clin Proc. 2011 Jul. 86(7):649-57. [Medline]. [Full Text].

  130. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010 Feb 23. 121(7):e46-e215. [Medline].

  131. Magee LA, Helewa M, Moutquin J-M et al. Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy. Journal of Obstetrics and Gynaecology Canada. March 2008. 30:S1-S48.

  132. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000 Apr 19. 283(15):1967-75. [Medline].

  133. Narkiewicz K. Diagnosis and management of hypertension in obesity. Obes Rev. 2006 May. 7(2):155-62. [Medline].

  134. National Institutes of Health. Your Guide to Lowering Your Blood Pressure With DASH. April 2006. 64. [Full Text].

  135. Novartis. Novartis announces termination of ALTITUDE study with Rasilez/Tekturna in high-risk patients with diabetes and renal impairment [press release]. December 20, 2011. Available at http://www.novartis.com/newsroom/media-releases/en/2011/1572562.shtml. Accessed: February 22, 2012.

  136. O'Connor PJ, Vazquez-Benitez G, Schmittdiel JA, Parker ED, Trower NK, Desai JR, et al. Benefits of Early Hypertension Control on Cardiovascular Outcomes in Patients With Diabetes. Diabetes Care. 2012 Sep 10. [Medline].

  137. O'Riordan M. Olmesartan label to include intestinal problems, FDA says. Medscape Medical News. July 3, 2013. [Full Text].

  138. Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog Cardiovasc Dis. 2009 Mar-Apr. 51(5):371-80. [Medline].

  139. Pleis JR, Lucus JW, Ward BW. Summary health statistics for US adults: National Health Interview Survey, 2008. Vital Health Stat 10. 2009. No. 242:[Full Text].

  140. Podymow T, August P. Antihypertensive drugs in pregnancy. Semin Nephrol. 2011 Jan. 31(1):70-85. [Medline].

  141. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989 Sep 28. 321(13):868-73. [Medline].

  142. Rastan A, Krankenberg H, Müller-Hülsbeck S, et al. Improved renal function and blood pressure control following renal artery angioplasty: the renal artery angioplasty in patients with renal insufficiency and hypertension using a dedicated renal stent device study (PRECISION). EuroIntervention. 2008 Aug. 4(2):208-13. [Medline].

  143. Roberts CL, Ford JB, Algert CS, Antonsen S, Chalmers J, Cnattingius S, et al. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. BMJ Open. 2011 May 24. 1(1):e000101. [Medline]. [Full Text].

  144. Shook RP, Lee DC, Sui X, Prasad V, Hooker SP, Church TS, et al. Cardiorespiratory fitness reduces the risk of incident hypertension associated with a parental history of hypertension. Hypertension. 2012 Jun. 59(6):1220-4. [Medline].

  145. Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011 Jul 26. 343:d4366. [Medline]. [Full Text].

  146. Svetkey LP, Moore TJ, Simons-Morton DG, Appel LJ, Bray GA, Sacks FM, et al. Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study. J Hypertens. 2001 Nov. 19(11):1949-56. [Medline].

  147. Taubert D, Roesen R, Lehmann C, Jung N, Schomig E. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. JAMA. 2007 Jul 4. 298(1):49-60. [Medline].

  148. The World Health Report 2002-Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002. [Full Text].

  149. Tseng CD, Yen AM, Chiu SY, Chen LS, Chen HH, Chang SH. A predictive model for risk of prehypertension and hypertension and expected benefit after population-based life-style modification (KCIS No. 24). Am J Hypertens. 2012 Feb. 25(2):171-9. [Medline].

  150. Tymchak W, Armstrong PW, Westerhout CM, Sookram S, Brass N, Fu Y, et al. Mode of hospital presentation in patients with non-ST-elevation myocardial infarction: implications for strategic management. Am Heart J. 2011 Sep. 162(3):436-43. [Medline].

  151. US Food and Drug Administration. FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. July 3, 2013. [Full Text].

  152. Wallach R, Karp RB, Reves JG, Oparil S, Smith LR, James TN. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol. 1980 Oct. 46(4):559-65. [Medline].

  153. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011 Mar. 57(3):413-20. [Medline].

  154. Wolz M, Cutler J, Roccella EJ, Rohde F, Thom T, Burt V. Statement from the National High Blood Pressure Education Program: prevalence of hypertension. Am J Hypertens. 2000 Jan. 13(1 Pt 1):103-4. [Medline].

  155. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Intern Med. 1991 Sep. 151(9):1786-92. [Medline].

 
Previous
Next
 
Anteroposterior x-ray from a 28-year old woman who presented with congestive heart failure secondary to her chronic hypertension, or high blood pressure. The enlarged cardiac silhouette on this image is due to congestive heart failure due to the effects of chronic high blood pressure on the left ventricle. The heart then becomes enlarged, and fluid accumulates in the lungs, known as pulmonary congestion.
Electrocardiogram (ECG) from a 47-year-old man with a long-standing history of uncontrolled hypertension. This image shows left atrial enlargement and left ventricular hypertrophy.
Electrocardiogram (ECG) from a 46-year-old man with long-standing hypertension. This ECG shows left atrial abnormality and left ventricular hypertrophy with strain.
Hypertrophied cardiac myocytes with enlarged "box car" nuclei.
Table 1. NHIS/NCHS Age-Adjusted Prevalence Estimates in Individuals Aged 18 Years and Older in 2008.
Race/Ethnic Group Have Hypertension, % Have Heart Disease, % Have Coronary Heart Disease, % Have Had a Stroke, %
White only 23.3 12.1 6.5 2.7
Black/African American 31.8 10.2 5.6 3.6
Hispanic/Latino 21.0 8.1 5.7 2.6
Asian 21.0 5.2 2.9 1.8
American Indian/Alaska Native 25.3 12.1 6.6 (this number is considered unreliable) 3.9 (this number is considered unreliable)
Source:  Pleis JR, Lucus JW, Ward BW. Summary health statistics for US adults: National Health Interview Survey, 2008. Vital Health Stat 10. No. 242; 2009. Available at: http://www.cdc.gov/nchs/data/series/sr_10/sr10_242.pdf. Accessed: February 21, 2012.



NCHS = National Center for Health Statistics; NHIS = National Health Interview Survey.



Table 2. Identifiable Hypertension and Screening Tests
Condition Screening Test
Chronic kidney disease Estimated glomerular filtration rate
Coarctation of the aorta Computed tomography angiography
Cushing syndrome; other states of glucocorticoid excess (eg, chronic steroid therapy Dexamethasone suppression test
Drug-induced/drug-related hypertension* Drug screening
Pheochromocytoma 24-hour urinary metanephrine and normetanephrine
Primary aldosteronism, other states of mineralocorticoid excess 24-hour urinary aldosterone level, specific mineralocorticoid tests
Renovascular hypertension Doppler flow ultrasonography, magnetic resonance angiography, computed tomography angiography
Sleep apnea Sleep study with oxygen saturation (screening would also include the Epworth Sleepiness Scale [ESS])
Thyroid/parathyroid disease Thyroid stimulating hormone level, serum parathyroid hormone level
Adapted from:  Chobanian AV, Bakris GL, Black HR, et al, and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. Dec 2003;42(6):1206-52.[3]



* Some examples of agents that induce hypertension include nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors; illicit drugs; sympathomimetic agents; oral contraceptive or adrenal steroid hormones; cyclosporine and tacrolimus; licorice; erythropoietin; and certain over-the-counter dietary supplements and medicines, such as ephedra, ma huang, and bitter orange. Drug-related causes of hypertension may be due to nonadherence, inadequate doses, and inappropriate combinations.



Table 3. Hypertensive Disorders in Pregnancy
Classification Characteristics
Chronic hypertension Prepregnancy or before 20 weeks’ gestation; SBP =140 mm Hg or DBP 90 mm Hg that persists >12 weeks postpartum
Preeclampsia After 20 weeks’ gestation; SBP =140 mm Hg or DBP 90 mm Hg with proteinuria (>300 mg/24 h)



Can progress to eclampsia



More common in nulliparous women, multiple gestation, women with hypertension =4 years, family history of preeclampsia, previous hypertension in pregnancy, and renal disease



Chronic hypertension with superimposed preeclampsia New-onset proteinuria after 20 weeks in hypertensive woman



In a woman with hypertension and proteinuria before 20 weeks’ gestation



Sudden 2- to 3-fold increase in proteinuria



Sudden increase in BP



Thrombocytopenia



Elevated AST or ALT levels



Gestational hypertension Temporary diagnosis



Hypertension without proteinuria after 20 weeks’ gestation



May be a preproteinuric phase of preeclampsia or a recurrence of chronic hypertension that abated in mid-pregnancy



May lead to preeclampsia



Severe cases may cause higher rates of premature delivery and growth retardation relative to mild preeclampsia



Transient hypertension Diagnosis made retrospectively



BP returns to normal by 12 weeks’ postpartum



May recur in subsequent pregnancies



Predictive of future primary hypertension



ALT = alanine aminotransferase; AST = aspartate aminotransferase; BP = blood pressure; DBP = diastolic BP; SBP = systolic BP.



Adapted from:  Chobanian AV, Bakris GL, Black HR, et al, and the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. Dec 2003;42(6):1206-52.[3]



Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.